People: Biomarin Pharmaceutical Inc (BMRN.OQ)
18 Oct 2019
Mr. Daniel Keith Spiegelman is Chief Financial Officer, Executive Vice President of BioMarin Pharmaceutical Inc. He joined BioMarin in May 2012 and currently serves as our Executive Vice President and Chief Financial Officer. From May 2009 until May 2012, Mr. Spiegelman served as a consultant to provide strategic financial management support to a portfolio of public and private life science companies. From 1998 to 2009, he served as Senior Vice President and Chief Financial Officer of CV Therapeutics, Inc. where he was responsible for finance, accounting, investor relations, business development, and information systems. From 1991 to 1998, Mr. Spiegelman served in various roles at Genentech, Inc., most recently as Treasurer. He received a B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business. Mr. Spiegelman is currently a director of Cascadian Therapeutics, Inc., a public biotechnology company.
|Total Annual Compensation, USD||559,231|
|Restricted Stock Award, USD||2,133,050|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||1,949,600|
|Fiscal Year Total, USD||4,641,880|